Company / Cash & Equivalents
Pfizer Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.1B
FY2025
5-year range
$416.0M / $2.9B
FY2021-FY2025
Trend
+9.5%
vs FY2024
Sector context
#19 of 207
Health Care
What the data says
Among 207 Health Care companies, Pfizer is in the top 9% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $416M in FY2022 to $3.3B in FY2016.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of -8.6%. Top quartile in the Health Care sector.
Declined from $2.9B to $1.1B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +40.0%
- 5-Year CAGR
- -8.6%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 207This company $1.1B Sector average $669.5M
▼
+70.6% above sector average
Key checks
Key Insights
- 5-year CAGR of -8.6%, indicating a declining trend.
- In FY2025, cash & equivalents increased 9.5% year-over-year.
- Ranks #19 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +9.5% |
| FY2024 | $1.0B | -63.4% |
| FY2023 | $2.9B | +585.8% |
| FY2022 | $416.0M | -78.6% |
| FY2021 | $1.9B | +8.8% |
| FY2020 | $1.8B | +59.3% |
| FY2019 | $1.1B | -1.6% |
| FY2018 | $1.1B | -15.1% |
| FY2017 | $1.3B | -59.9% |
| FY2016 | $3.3B | -8.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026